Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab, quantity: 150 mg - injection, solution - excipient ingredients: histidine; sucrose; polysorbate 20; water for injections - primary hypercholesterolaemia praluent is indicated as an adjunct to diet and exercise to reduce ldl-c in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk: - in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with maximum tolerated dose of a statin, - alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach ldl-c goals. praluent-ccdsv12-piv9-d3-30sep22 page 2 of 35 prevention of cardiovascular events praluent is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab, quantity: 75 mg - injection, solution - excipient ingredients: histidine; sucrose; polysorbate 20; water for injections - primary hypercholesterolaemia praluent is indicated as an adjunct to diet and exercise to reduce ldl-c in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk: - in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with maximum tolerated dose of a statin, - alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach ldl-c goals.,prevention of cardiovascular events praluent is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab, quantity: 150 mg - injection, solution - excipient ingredients: histidine; sucrose; polysorbate 20; water for injections - primary hypercholesterolaemia praluent is indicated as an adjunct to diet and exercise to reduce ldl-c in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk: - in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with maximum tolerated dose of a statin, - alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach ldl-c goals.,prevention of cardiovascular events praluent is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies (see section 5.1 pharmacodynamic properties, clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - alirocumab, quantity: 75 mg - injection, solution - excipient ingredients: histidine; sucrose; polysorbate 20; water for injections - primary hypercholesterolaemia praluent is indicated as an adjunct to diet and exercise to reduce ldl-c in adults with primary (heterozygous familial or non-familial) hypercholesterolaemia in patients with moderate to very high cardiovascular risk: - in combination with a statin, or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with maximum tolerated dose of a statin, - alone or in combination with other lipid lowering therapies in patients who are statin intolerant or for whom a statin is contraindicated who are unable to reach ldl-c goals.,prevention of cardiovascular events praluent is indicated to reduce the risk of cardiovascular events (myocardial infarction, stroke, unstable angina requiring hospitalisation) in adults with established cardiovascular disease, in combination with optimally dosed statins and/or other lipid-lowering therapies (see section 5.1 pharmacodynamic properties, clinical trials).

United States - English - NLM (National Library of Medicine)

aventis pharmaceuticals inc. - triamcinolone acetonide (unii: f446c597ka) (triamcinolone - unii:1zk20vi6ty) - 55 ug

United States - English - NLM (National Library of Medicine)

aventis pharmaceuticals, inc. - triamcinolone acetonide (unii: f446c597ka) (triamcinolone - unii:1zk20vi6ty) - 55 ug

United States - English - NLM (National Library of Medicine)

aventis pharma ltd. - oxaliplatin (unii: 04zr38536j) (oxaliplatin - unii:04zr38536j) - oxaliplatin 5 mg in 1 ml

United States - English - NLM (National Library of Medicine)

aventis pharmaceuticals inc. - indapamide (unii: f089i0511l) (indapamide - unii:f089i0511l) - 1.25 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - promethazine hydrochloride, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; maize starch; macrogol 200; lactose monohydrate; hypromellose; povidone; titanium dioxide; indigo carmine; purified water; industrial methylated spirit - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria, contact dermatitis, and allergic reactions to insect bites and stings. upper respiratory tract: relief of excesive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis. nausea and vomiting: antiemetic in vomiting of various causes, including post-operative vomiting, irradiation sickness, drug induced nausea, and motion sickness. sedation: for short term use on the advice of a doctor or pharmacist.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis healthcare pty ltd t/a sanofi consumer healthcare - promethazine hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; lactose monohydrate; povidone; maize starch; macrogol 200; titanium dioxide; indigo carmine; purified water; industrial methylated spirit - allergies: treatment of allergic conditions including some allergic reactions to drugs, urticaria, contact dermatitis, and allergic reactions to insect bites and stings. upper respiratory tract: relief of excesive secretion in the upper respiratory tract as a result of hayfever and allergic rhinitis. nausea and vomiting: antiemetic in vomiting of various causes, including post-operative vomiting, irradiation sickness, drug induced nausea, and motion sickness. sedation: for short term use on the advice of a doctor or pharmacist.